Enter multiple symbols separated by commas

Eli Lilly's CEO on Prescription for Profits

Wednesday, 25 Apr 2012 | 7:10 AM ET

John Lechleiter, Eli Lilly chairman & CEO breaks down his company's earnings results of an adjusted $0.92 a share versus estimates of $0.78 est. and a look at the drug maker's generic challenges, and the politics of prescriptions.